I have been looking through articles for the better part of a week to find the reference I referred to in a post early in this thread. Finally, eureka! I think I have it. The link to the abstract of the article, titled, "The Dilemma of the Strive for Apoptosis in Oncology: Mind the Heart" is here:
http://www.ncbi.nlm.nih.gov/entrez/q...&dopt=Abstract. Unfortunately, the article is copyrighted and not available for free. I wanted to read it badly enough that I ponied up the $30.00. If you do the same, go to page 13, there is a paragraph that reads:
"A promising new technique for in vivo detection of Her2 is radiolabled trastuzumab gammacamera imaging. This approach appears to be valuable for prediction of cardiotoxicity in Her2 positive breast cancer patients when performed before trastuzumab treatment. (99, 100) Radiolabeled trastuzumab scintigraphy may also contribute to our understanding of CHF pathophysiology. Furthermore, since trastuzumab enhances anthracycline induced cardiotoxicity, it may be of value for the detection of cardiac injury by anthracyclines. Serum detection of the shed extracellular domain of Her2 is also interesting in this regard and may serve as a prognostic marker for CHF."
The two cited foot notes are to the following articles:
99. Behr TM, Behe M, Wormann B, Trastuzumab and Breast Cancer. N Engl J Med 2001; 345:995-996.
100. Lub-De Hoog MN, Perik PJ, Gietema JA, et. al. Biodistribution and pharmokinetics of radiolabled trastuzumab in Her2-positive metastatic breast cancer. Proc Am Soc Clin Oncol 2004, 22abstr3063.
Both of these articles are also copyright protected and not available for free. Seems you really need to want to know this stuff to find it out. Anyway, I wanted to follow up with the information I promised. Hope this is helpful to those who are interested.
Hopeful
Hybrid Mode
